A5001469994- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Tuberculosis Research and Epidemiology
- Gastrointestinal Tumor Research and Treatment
- Diagnosis and treatment of tuberculosis
- Immunodeficiency and Autoimmune Disorders
- Gastrointestinal disorders and treatments
- Occupational and environmental lung diseases
- Helicobacter pylori-related gastroenterology studies
- Neonatal Health and Biochemistry
- Esophageal and GI Pathology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Youth, Drugs, and Violence
- Cerebrovascular and genetic disorders
- Parasitic Infections and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Sarcoidosis and Beryllium Toxicity Research
- Galectins and Cancer Biology
- Gastric Cancer Management and Outcomes
- Cardiovascular and Diving-Related Complications
- Congenital Heart Disease Studies
- Nausea and vomiting management
- Soft tissue tumor case studies
- Korean Peninsula Historical and Political Studies
Universidade Federal de Juiz de Fora
2019-2022
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2006
Abstract Background The effectiveness of ustekinumab (UST) in the treatment Crohn’s disease (CD) has been demonstrated pivotal Phase 3 UNITI 1 and 2 IM-UNITI studies both anti-TNF-naïve anti-TNF-exposed patients. Given selective nature trial designs, real-world safety are warranted. We report our experience with UST a large, multicenter cohort Brazilian patients CD. Methods performed retrospective study including CD, predominantly biologically refractory who received UST. primary endpoint...
The etiology of inflammatory bowel disease (IBD) is unknown, but it believed to be multifactorial. hygiene hypothesis proposes that better conditions would lead less infectious during childhood and favor the development immune-mediated diseases.To test in IBD by assessing environmental risk factors associated with different regions Brazil diverse socioeconomic indices.A multicenter case-control study was carried out 548 Crohn's (CD) 492 ulcerative colitis (UC) outpatients 416 healthy...
ABSTRACT BACKGROUND: Small intestinal bacterial overgrowth (SIBO) appears to be common in patients with Crohn’s disease (CD). The rate of SIBO has been estimated at 25%-88% this setting. However, different demographic, socioeconomic, and disease-related factors may exist between South American North or European populations that limit the generalization these findings, as data are mainly derived from studies. OBJECTIVE: We studied prevalence predictors CD outpatients. METHODS: In...
Pemphigus vulgaris (PV) is a chronic autoimmune mucocutaneous disease. In most cases, the initial manifestation occurs in mouth as multiple ulcerations preceded by blisters that rupture and later spread to other mucous membranes skin. Esophageal impairment rare. We report case of PV with esophageal involvement 53-year-old woman who sought medical care, complaining diffuse painful lesions oral cavity for approximately 1 month, no improvement nystatin. Upper digestive endoscopy (UDE) was...
Ustekinumab (UST) is a fully human monoclonal antibody against IL-12/23. UST induced clinical response and maintained higher rate of than placebo in patients with Crohn's disease (CD). was approved Brazil November 2017. Real-world data regarding efficacy safety to CD lacking our country. We report experience use refractory anti-TNF therapy. An open-label prospective not controlled study performed including from five academic medical centres severely active, starting on (IV infusions followed...
BACKGROUND: Ustekinumab (UST)is a fully human monoclonal antibody against IL-12/23 approved in Brazil for the treatment of moderate-to-severe Crohn’s disease (CD) November 2017. UST has demonstrated its efficacy induction and maintenance therapy patients with CD. Real world data regarding safety this population is lacking our country. We hereby report experience moderate to severe METHODS: A retrospective chart review prospective study were performed including from eleven IBD referral...